65. Use of ~~A method of preventing pain, comprising administering~~ a prophylactically effective amount of the composition of matter of any of Claims 1, 30, 31, 37, 41, 45, 49, 53, 54, or 59-63 in the manufacture of a medicament for preventing pain.

66. Use of ~~A method of treating pain, comprising administering~~ a therapeutically effective amount of the composition of matter of any of Claims 1, 30, 31, 37, 41, 45, 49, 53, 54, or 59-63 in the manufacture of a medicament for treating pain.

67. The ~~method~~ use of Claim 66, wherein the pain is chronic pain, acute pain, or persistent pain.

68. The ~~method~~ use of Claim 67, wherein the chronic pain is associated with cancer, chemotherapy, osteoarthritis, fibromyalgia, primary erythromelalgia, post-herpetic neuralgia, painful diabetic neuropathy, idiopathic painful neuropathy, neuromas, paroxysmal extreme pain disorder, migraine, trigeminal neuralgia, orofacial pain, cluster headaches, complex regional pain syndrome (CRPS), failed back surgery syndrome, sciatica, interstitial cystitis, pelvic pain, lower back pain, inflammation-induced pain, or joint pain.

69. The ~~method~~ use of Claim 67, wherein the acute or persistent pain is associated with trauma, burn, or surgery.

70. The composition of matter of Claim 1 or 30, wherein X_{aa}^{29} is an acidic or neutral hydrophilic residue.

71. The composition of matter of Claim 70, wherein X_{aa}^{29} is selected from Ala, Asp, Glu, Gly, Asn, Gln, Ser, Thr, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.

72. The composition of matter of Claim 70, comprising an amino acid sequence selected from SEQ ID NOS: 1071-2798.